drugset / Trial / NCT01646268

Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients

NCT01646268

Phase 3 Completed 249 enrolled UCB Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective is to demonstrate that the Rotigotine transdermal patch is efficacious in Chinese subjects with early-stage idiopathic Parkinson's disease.

Timeline

Start
2012-07
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 8 mg Other

Indications